Cargando…

Clinical and Pathological Evidence of Anti-GD2 Immunotherapy Induced Differentiation in Relapsed/Refractory High-Risk Neuroblastoma

SIMPLE SUMMARY: The anti-tumor activity of anti-GD2 monoclonal antibodies (mAbs) have been demonstrated by the capacity to mediate immunological cytotoxicity but also through direct cell death induction. Recently, studies with anti-GD2 mAbs for high-risk (HR)-neuroblastoma (NB) patients with measura...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mora, Jaume, Castañeda, Alicia, Colombo, Maria Cecilia, Gorostegui, Maite, Gomez, Fernando, Mañe, Salvador, Santa-Maria, Vicente, Garraus, Moira, Macias, Napoleon, Perez-Jaume, Sara, Muñoz, Oscar, Muñoz, Juan Pablo, Barber, Ignasi, Suñol, Mariona
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7998131/ https://www.ncbi.nlm.nih.gov/pubmed/33809255 http://dx.doi.org/10.3390/cancers13061264

Ejemplares similares

The Role of Autologous Stem-Cell Transplantation in High-Risk Neuroblastoma Consolidated by anti-GD2 Immunotherapy. Results of Two Consecutive Studies
por: Mora, Jaume, et al.
Publicado: (2020)

Naxitamab Combined with Granulocyte-Macrophage Colony-Stimulating Factor as Consolidation for High-Risk Neuroblastoma Patients in First Complete Remission under Compassionate Use—Updated Outcome Report
por: Mora, Jaume, et al.
Publicado: (2023)

Early Salvage Chemo-Immunotherapy with Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term Outcomes
por: Muñoz, Juan Pablo, et al.
Publicado: (2023)

Novel infusion strategy reduces severe adverse events caused by the anti-GD2 monoclonal antibody naxitamab
por: Varo, Amalia, et al.
Publicado: (2023)

How we approach the treatment of patients with high-risk neuroblastoma with naxitamab: experience from the Hospital Sant Joan de Déu in Barcelona, Spain
por: Castañeda, A., et al.
Publicado: (2022)

Corrigendum to “How we approach the treatment of patients with high-risk neuroblastoma with naxitamab: experience from the Hospital Sant Joan de Déu in Barcelona, Spain”: [ESMO Open, 7 (2022) 100462]
por: Castañeda, A., et al.
Publicado: (2022)

Multiparametric MRI evaluation of bone sarcomas in children
por: Inarejos Clemente, Emilio J., et al.
Publicado: (2022)

Prognostic value of patient‐derived xenograft engraftment in pediatric sarcomas
por: Castillo‐Ecija, Helena, et al.
Publicado: (2021)

AC-265347 Inhibits Neuroblastoma Tumor Growth by Induction of Differentiation without Causing Hypocalcemia
por: Gonçalves-Alves, Eliana, et al.
Publicado: (2022)

MIF/CXCR4 signaling axis contributes to survival, invasion, and drug resistance of metastatic neuroblastoma cells in the bone marrow microenvironment
por: Garcia-Gerique, Laura, et al.
Publicado: (2022)

Cinacalcet inhibits neuroblastoma tumor growth and upregulates cancer-testis antigens
por: Rodríguez-Hernández, Carlos J., et al.
Publicado: (2016)

Total calcaneal allograft reconstruction of an Ewing's sarcoma in a child: Outcome and review of the literature
por: Torner, Ferran, et al.
Publicado: (2022)

DNA Hypomethylation Affects Cancer-Related Biological Functions and Genes Relevant in Neuroblastoma Pathogenesis
por: Mayol, Gemma, et al.
Publicado: (2012)

Autologous Stem-Cell Transplantation for High-Risk Neuroblastoma: Historical and Critical Review
por: Mora, Jaume
Publicado: (2022)

LGG-29. Use of Bevacizumab in Pediatric Low-grade Glioma: Ten-year experience in a single center
por: Rafael, Margarida Simão, et al.
Publicado: (2022)

Global Impact of Monoclonal Antibodies (mAbs) in Children: A Focus on Anti-GD2
por: Larrosa, Cristina, et al.
Publicado: (2023)

Expression of the neuron-specific protein CHD5 is an independent marker of outcome in neuroblastoma
por: Garcia, Idoia, et al.
Publicado: (2010)

Expansive Oral Giant Cell Granuloma in a Pediatric Patient
por: Cahuana-Bartra, Pau, et al.
Publicado: (2023)

Outpatient administration of naxitamab in combination with granulocyte‐macrophage colony‐stimulating factor in patients with refractory and/or relapsed high‐risk neuroblastoma: Management of adverse events
por: Mora, Jaume, et al.
Publicado: (2022)

Correspondence on "G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment" by Martinez Sanz et al
por: Mora, Jaume, et al.
Publicado: (2021)

Long-term continuous infusion of anti-GD2 antibody CH14.18/CHO in relapsed/refractory neuroblastoma patients
por: Lode, Holger, et al.
Publicado: (2013)

Disialogangliosides GD2 and GD3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteins
Publicado: (1986)

EpiGe: A machine-learning strategy for rapid classification of medulloblastoma using PCR-based methyl-genotyping
por: Gómez-González, Soledad, et al.
Publicado: (2023)

Anti-GD2 mAb and Vorinostat synergize in the treatment of neuroblastoma
por: Kroesen, Michiel, et al.
Publicado: (2016)

Anti-GD2 Directed Immunotherapy for High-Risk and Metastatic Neuroblastoma
por: Chan, Godfrey Chi-Fung, et al.
Publicado: (2022)

Parathyroid hormone‐like hormone plays a dual role in neuroblastoma depending on PTH1R expression
por: García, Marta, et al.
Publicado: (2019)

Polymorphisms in the Calcium-Sensing Receptor Gene Are Associated with Clinical Outcome of Neuroblastoma
por: Masvidal, Laia, et al.
Publicado: (2013)

Follow‐up of intraocular retinoblastoma through the quantitative analysis of conserved nuclear DNA sequences in aqueous humor from patients
por: Cuadrado‐Vilanova, Maria, et al.
Publicado: (2022)

Neuroblastoma GD2 Expression and Computational Analysis of Aptamer-Based Bioaffinity Targeting
por: Sabbih, Godfred O., et al.
Publicado: (2021)

GD2 Expression in Medulloblastoma and Neuroblastoma for Personalized Immunotherapy: A Matter of Subtype
por: Paret, Claudia, et al.
Publicado: (2022)

Genomic ALK alterations in primary and relapsed neuroblastoma
por: Rosswog, Carolina, et al.
Publicado: (2023)

Novel Therapies for Relapsed and Refractory Neuroblastoma
por: Zage, Peter E.
Publicado: (2018)

Alterations in neuroblastoma ganglioside synthesis by induction of GD1b synthase by retinoic acid
por: Hettmer, S, et al.
Publicado: (2004)

IgA antibody immunotherapy targeting GD2 is effective in preclinical neuroblastoma models
por: Stip, Marjolein C, et al.
Publicado: (2023)

Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment
por: Seitz, Christian Martin, et al.
Publicado: (2021)

Targeting GD2-positive Refractory/Resistant Neuroblastoma and Osteosarcoma with Anti- CD3 x Anti-GD2 Bispecific Antibody Armed T cells
por: Yankelevich, Maxim, et al.
Publicado: (2023)

Comprehensive characterization of neuroblastoma cell line subtypes reveals bilineage potential similar to neural crest stem cells
por: Acosta, Sandra, et al.
Publicado: (2009)

Different Subcellular Localization of ALCAM Molecules in Neuroblastoma: Association with Relapse
por: Corrias, Maria Valeria, et al.
Publicado: (2010)

Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome
por: Padovan-Merhar, Olivia M., et al.
Publicado: (2016)

Targeting MYCN and ALK in resistant and relapsing neuroblastoma
por: Tucker, Elizabeth R, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_nr84vu59pl67os1qc62e3ap20p